Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$57.02 USD

57.02
591,898

+0.73 (1.30%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $57.03 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) slew of strategic deals raises optimism about the stock.

Tracey Ryniec headshot

5 Cheap Healthcare Stocks in 2022

by Tracey Ryniec

Energy, banks and agriculture have plenty of value stocks this year but what about healthcare?

Cooper Companies (COO) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal third-quarter results are likely to reflect segmental strength.

Fresenius Medical (FMS) Robust Product Portfolio Drives Growth

by Zacks Equity Research

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Catalent (CTLT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q4 results are likely to have been driven by robust segmental performances.

3 Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

AMN vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

Phibro (PAHC) Q4 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Phibro (PAHC) posts better-than-expected revenues for the fiscal fourth quarter, with robust growth across all segments.

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Abbott (ABT) to Offer New Treatment Option for Chronic Pain

by Zacks Equity Research

Abbott's (ABT) Proclaim Plus SCS system with FlexBurst360 therapy will cater to the changing needs of patients with chronic pain.

Here's Why You Should Retain Exact Sciences (EXAS) Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences' (EXAS) better-than-expected results and robust Cologuard volumes.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Medtronic (MDT) posts better-than-expected results for the fiscal first quarter and maintains earnings and sales outlook for the full year.

3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.

Here's Why You Should Buy McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks.com featured highlights include AMN Healthcare, Encore Wire, Veritiv and SP Plus

by Zacks Equity Research

AMN Healthcare, Encore Wire, Veritiv and SP Plus have been highlighted in this Screen of The Week article.

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.

Thermo Fisher (TMO) to Offer Wheat & Sesame Allergy Testing

by Zacks Equity Research

Thermo Fisher's (TMO) ImmunoCAP blood tests receive FDA approval for wheat and sesame allergy diagnosis.

Here's Why You Should Buy ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen's (NXGN) solid product portfolio and continued demand for its solutions raise optimism about the stock.

Moumita C. Chattopadhyay headshot

4 High-Flying Stocks With Rising Cash Flows to Buy Now

by Moumita C. Chattopadhyay

Companies with rising cash flows like AMN, WIRE, VRTV and SP are worth buying.

Zacks.com featured highlights include AMN Healthcare, Earthstone Energy and Hanmi Financial

by Zacks Equity Research

AMN Healthcare, Earthstone Energy and Hanmi Financial have been highlighted in this Screen of The Week article.

QIAGEN's (QGEN) New Syndromic Test to Combat Monkeypox Spread

by Zacks Equity Research

QIAGEN (QGEN) joins the global fight against monkeypox with the launch of its novel QIAstat-Dx Viral Vesicular Panel RUO.

Here's Why You Should Hold on to Catalent (CTLT) Stock Now

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Teleflex (TFX) Hit by Urolift Volume Decline, Cost Pressure

by Zacks Equity Research

In the Americas, growth within the Surgical business of Teleflex (TFX) is offset by a decline in Interventional Urology.